Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate
the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or
borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial
staging using institutional standard methods. If the participant is prescribed neoadjuvant
therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned
surgical resection. This will be followed by histopathology and IHC analyses and comparison
to resected PDAC tumor specimens.